|
|
| Company |
| TotipotentRx was originally founded in 2011 in California. The Company is a biotherapeutic company specializing in the development of cell-based therapeutics in the field of regenerative medicine, including endo- and cardiovascular diseases, orthopedic diseases, diabetic foot ulcer and wound care. |
|
|
| Company History |
- 2011 - TotipotentRx was founded in Los Angeles, California
- 2013 - TotipotentRx merged with ThermoGenesis Corp (Nasdaq:KOOL)
- 2016 - Published 40-month PhaseI/II clinical date for treating critical limb ischemia
- 2017 - Received U.S. FDA acceptance letter for the amended Phase III trial design
- 2018 - New Point-of-Care platform developed by ThermoGenesis, potentially be used for diabetic foot ulcer and other indications
- 2019 - All clinical assets spun off from ThermoGenesis into ImmuneCyte Inc
- 2021 - ImmuneCyte Inc accquired Boyalife Genomics Tianjin and its 160,000 sq.ft R&D center
|
|
|
|
